Hansoh Pharmaceutical (03692) Announces HS-10502 Tablet Receives IND Approval for Advanced Solid Tumors

Hansoh Pharma (03692) announced that "HS-10502 Tablets," a Class 1 new drug independently developed by its subsidiary Jiangsu Hansoh Pharmaceutical Group Co., Ltd., has received the clinical trial notification issued by the China National Medical Products Administration. It is intended for the treatment of advanced solid tumors, with specific indications to be determined after clinical trials.